An official website of the United States government
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Trial Status: administratively complete
The main objective of this study is to determine the progression free survival of
umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase)
inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib,
duvelisib, other).
Inclusion Criteria
Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
Discontinuation on prior BTK inhibitor or PI3K delta inhibitor due to adverse events within prior 9 months
Presence of measurable disease
Exclusion Criteria
Progression on prior BTK or PI3K delta inhibitor
Prior treatment with TGR-1202
Richter's transformation or CLL transformation to aggressive lymphoma
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02742090.
Locations matching your search criteria
United States
District of Columbia
Washington
MedStar Georgetown University Hospital
Status: Active
Name Not Available
New Hampshire
Lebanon
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
